Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...
Scientists from CSIR-Central Drug Research Institute have discovered that targeting the enzyme acyl-CoA synthetase 4 (ACSL4) ...
At 15 years, patients who had received immediate surgery had lower rates of distant recurrence and breast cancer death.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback